@alongi_filippo @Icro_Meattini @RadiotherapyOn1 @ESTRO_RT ... or, re: low-toxicity radiation, these Brits (and other countries too!) https://t.co/PSDq2U0W5y
TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain, travel, cost ⬇︎deaths (heart/lung/other cancers) ⬆quality of life ⬆survival for grade 1 or 2 cancers https://t.co/H6nBwLH2WW https
RT @jsvaidya: TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain,…
We pointed out that the LR rate was only reported in tabular form in the 2020 update (https://t.co/yiFt9YG8LH). In graphical form, the composite LRFS was reported, which was new and not specified in the original protocol (4/13)
RT @toddscarbrough: I would submit as much as @CShahMD and some other people have skepticism over TARGIT-A and @jsvaidya et al data There…
RT @jsvaidya: TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain,…
TARGIT-IORT with lumpectomy for #breastcancer effectively substitutes post op radiation, improves quality of life,reduces pain,harms of overdiagnosis & nonbreastcancer deaths; improves survival if grade 1or2 https://t.co/buFBGgdugN https://t.co/4ry5ZU
RT @jsvaidya: TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain,…
RT @jsvaidya: TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain,…
RT @jsvaidya: TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain,…
TARGIT-IORT during lumpectomy is better than post-op whole breast radiotherapy: = equally effective for #breastcancer ⬇︎pain, travel, cost ⬇︎deaths (heart/lung/other cancers) ⬆quality of life ⬆survival for grade 1 or 2 cancers https://t.co/3lLFCra4Vj https
The 10-year update was eagerly anticipated by many in attempt to shed light on the topic and allow us to put TARGIT into context. The whole study was split in tw but see the pre-path results here: https://t.co/yiFt9YG8LH
RT @jsvaidya: #RCT evidence https://t.co/WvCo6ZpKws https://t.co/4ry5ZU3cUY Compare #breastcancer #radiotherapy treatments https://t.co/yY…
#RCT evidence https://t.co/WvCo6ZpKws https://t.co/4ry5ZU3cUY Compare #breastcancer #radiotherapy treatments https://t.co/yY1NIGEnpO TARGIT-IORT v ELIOT https://t.co/MRfJYfuOQL TARGIT-IORT is better for patients https://t.co/RULs4Oibh3 UCL-hosted lecture
This treatment should be available to ALL early stage breast cancer sufferers @NHSEngland https://t.co/fMb3draOFx
RT @jsvaidya: #NCRIFestival TARGIT-IORT during lumpectomy for #breastcancer: saves time, money, travel, CO2 #COP26 ; reduces non-br ca deat…
#NCRIFestival TARGIT-IORT during lumpectomy for #breastcancer: saves time, money, travel, CO2 #COP26 ; reduces non-br ca deaths, improves overall survival for grade 1 or 2 cancers: better for patients than whole breast radiotherapy https://t.co/buFBGgdugN
TARGIT-A outcomes: 1) Controversial 2) Inflammatory (to many) 3) Based on long-term, multi-institutional, randomized data from thousands of patients 4) Catching on (just a teeny, tiny bit) in the U.S.?
@SirohiBhawna @ApolloProton @HospitalsApollo @vcare_ngo Indeed, safer & quicker treatments help: TARGIT-IORT during lumpectomy for breast cancer saves time, costs less, reduces pain, improves quality of life, reduces non-Br Ca deaths, & improves ov
RT @jsvaidya: Compared with whole breast radiotherapy, TARGIT-IORT during lumpectomy for breast cancer saves time, money, travel, CO2; with…
Compared with whole breast radiotherapy, TARGIT-IORT during lumpectomy for breast cancer saves time, money, travel, CO2; with fewer cardiovascular & other cancer deaths, improving overall survival in those with grade 1 or 2 cancers https://t.co/buFBGgd
Main results of the TARGIT-A trial are published in the BMJ https://t.co/buFBGgdugN
RT @jsvaidya: Risk-adapted single-dose TARGIT-IORT APBI: Enables most patients to complete their radiation during lumpectomy Breast cancer…
RT @carolinesouthal: #bccww #bcsm #radiotherapy @owisebreast
#bccww #bcsm #radiotherapy @owisebreast
Risk-adapted single-dose TARGIT-IORT APBI: Enables most patients to complete their radiation during lumpectomy Breast cancer control same as whole breast radiation & fewer other deaths Not limited to low-risk: 443 grade 3, 488 node pos, 426 ER/PgR nega
TARGIT-IORT during lumpectomy for #breastcancer is better for patients than whole-breast radiotherapy: As effective Greatly reduced non-breast-cancer deaths (10%→5%) Less pain & toxicity Improved quality of life & cosmetic outcome Lower cost to t
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial https://t.co/wAPIDrqBYd
RT @jsvaidya: TARGIT-IORT radiotherapy during breast cancer lumpectomy: Better for patients Effective cancer treatment 4.4% fewer non-br c…
RT @jsvaidya: TARGIT-IORT radiotherapy during breast cancer lumpectomy: Better for patients Effective cancer treatment 4.4% fewer non-br c…
TARGIT-IORT radiotherapy during breast cancer lumpectomy: Better for patients Effective cancer treatment 4.4% fewer non-br ca deaths ie 900 less/yr Saves NHS £9m/y Safer during COVID @NHSEngland @NICEComms https://t.co/vKplK5hxZ2 https://t.co/buFBGgdugN
@EuropHospital @ucl Here is a patient’s perspective. Also a short video explaining the latest paper https://t.co/fGDguskHBr Full paper https://t.co/vKplK5hxZ2 Blog about BJC paper https://t.co/456MkzqTz2
RT @jsvaidya: Marcelle wrote in the Telegraph about her breast cancer treatment with TARGIT-IORT radiotherapy in 2013 https://t.co/lumsgGn7…
RT @jsvaidya: Marcelle wrote in the Telegraph about her breast cancer treatment with TARGIT-IORT radiotherapy in 2013 https://t.co/lumsgGn7…
RT @jsvaidya: Marcelle wrote in the Telegraph about her breast cancer treatment with TARGIT-IORT radiotherapy in 2013 https://t.co/lumsgGn7…
Marcelle wrote in the Telegraph about her breast cancer treatment with TARGIT-IORT radiotherapy in 2013 https://t.co/lumsgGn71m Her thoughts 8 years on -> video: More information https://t.co/Z6mhYidARm Main paper https://t.co/WvCo6ZpKws Latest paper
8 out of 10 patients allocated TARGIT-IORT during lumpectomy completed their full treatment once the cancer operation was finished in one go, under the same anaesthetic and no further radiation was required post-operatively. https://t.co/WvCo6ZpKws
[with TARGIT-IORT compared with whole breast radiotherapy]...there were fewer deaths from causes other than breast cancer (cardiovascular or lung problems and other cancers) - a large 4.4% reduction by 12 years after surgery from 9.85% to 5.41%. https://t.
The large international randomised TARGIT-A trial (2298 patients) compared risk-adapted single-dose TARGIT-IORT during lumpectomy for breast cancer with post-operative whole breast radiotherapy given over several weeks. TARGIT-IORT was as effective and ...
@uclnews @MichaelBaum11 @jtobias100 @UCLDivofSurgery @uclmedsci This is consistent with the main outcomes of the TARGIT-A randomised trial single-dose TARGIT-IORT vs whole breast radiotherapy: No difference in breast cancer mortality and a reduced mortalit
RT @jsvaidya: Full @bmj_latest paper is at https://t.co/WvCo6ZpKws and further publications are at https://t.co/TLKgqiWynm
RT @jsvaidya: Full @bmj_latest paper is at https://t.co/WvCo6ZpKws and further publications are at https://t.co/TLKgqiWynm
Full @bmj_latest paper is at https://t.co/WvCo6ZpKws and further publications are at https://t.co/TLKgqiWynm
@ParikhSimul @CShahMD @ElenaSperk @mdAlvaradoMD @SorenBentzen @theRADSofKHAN @jsvaidya is it fair to say that the LR/IBTR rate was not revealed in TARGIT-A / BMJ 2020. I would have bet one dollar it was! Would I have lost money. https://t.co/PSDq2U0W5y
@mdAlvaradoMD @SorenBentzen @toddscarbrough @mdAlvaradoMD @ElenaSperk this data has still not been published. Check out Table 3 from pre-path: LR: IORT 60 vs. WBI 24, 2.5X increase with IORT. https://t.co/EpJdoX4Cw4 @SorenBentzen @theRADSofKHAN
The original paper describing long term results of TARGIT-A trial comparing risk-adapted single-dose TARGIT-IORT during lumpectomy for breast cancer vs. whole breast radiotherapy is here https://t.co/WvCo6ZpKws and a short video summary is here https://t.c
RT @jsvaidya: Two breast cancer treatments completed in one-go: TARGIT-IORT radiotherapy given during lumpectomy is as effective and so muc…
RT @jsvaidya: Two breast cancer treatments completed in one-go: TARGIT-IORT radiotherapy given during lumpectomy is as effective and so muc…
@HeikoEnderling @SMB_MathBiology @ara_anderson @mcapellanus ... those were indeed exciting times and 15 years on, the modelling predictions about effectiveness of single-dose TARGIT-IORT during lumpectomy for breast cancer have been confirmed in the long-t
@ErinGillespieMD @TheLancet @SorenBentzen @theRADSofKHAN @Icro_Meattini @Sushilberiwal @CahlonOren @HinaSaeedMD Dr. Douek also fails to acknowledge major concerns with IORT as discussed by @SorenBentzen (https://t.co/MeDyJ3PWQF) as well as recent editorial
#Swasthya December issue preview @jsvaidya writes about 'new' treatment option for #breastcancer IORT (Intraoperative radiotherapy) results recently published @bmj_latest https://t.co/TuagdAdiVn
RT @jsvaidya: Two breast cancer treatments completed in one-go: TARGIT-IORT radiotherapy given during lumpectomy is as effective and so muc…
RT @jsvaidya: Two breast cancer treatments completed in one-go: TARGIT-IORT radiotherapy given during lumpectomy is as effective and so muc…
Two breast cancer treatments completed in one-go: TARGIT-IORT radiotherapy given during lumpectomy is as effective and so much better for patients than the prolonged post-operative whole breast radiotherapy: TARGIT-A randomised trial long-term results http
RT @CroAviano: 🥼☢️ Tumore al seno, studio internazionale conferma l’efficacia della radioterapia intraoperatoria. Protagonista anche la Bre…
RT @bbckirstylang: Every patient with early breast cancer should be offered this form of radiotherapy. It’s scandalous to put women through…
RT @bbckirstylang: Every patient with early breast cancer should be offered this form of radiotherapy. It’s scandalous to put women through…
RT @RADMagazine: Read the clinical paper reported on in our September front page story here:
Read the clinical paper reported on in our September front page story here:
RT @jsvaidya: Here is the 1-page summary and the full paper is at https://t.co/WvCo6ZpKws https://t.co/dgGNUlEJb3
@RADMagazine Here is the 1-page BMJ summary and full paper related to the story on the front page https://t.co/WvCo6ZpKws https://t.co/2kjGLmlAAK
Here is the 1-page summary and the full paper is at https://t.co/WvCo6ZpKws https://t.co/dgGNUlEJb3
@RCSEd @clinicallibrar1 TARGIT-IORT during lumpectomy should be discussed with patients, pre-operatively. Long-term results of TARGIT-A trial found it be an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-
RT @BreastDocUK: For those wanting a quick intro into today's #radonc #jc topic of IORT in the TARGIT study I recommend the 4min video abst…
RT @jsvaidya: For improving #breastcancer treatment, risk-adapted single-dose radiotherapy given during lumpectomy proved to be as effectiv…
RT @jsvaidya: @Rad_Nation >= 45 years, invasive ductal cancer, unifocal on exam & imaging (≤3.5 cm, cN0-N1), suitable for lumpectomy/wide l…
RT @jsvaidya: @Rad_Nation >= 45 years, invasive ductal cancer, unifocal on exam & imaging (≤3.5 cm, cN0-N1), suitable for lumpectomy/wide l…
RT @jsvaidya: @Rad_Nation >= 45 years, invasive ductal cancer, unifocal on exam & imaging (≤3.5 cm, cN0-N1), suitable for lumpectomy/wide l…
@Rad_Nation >= 45 years, invasive ductal cancer, unifocal on exam & imaging (≤3.5 cm, cN0-N1), suitable for lumpectomy/wide local excision. MRI not required in the trial, but can be done if felt necessary joint decisions with MultiD team + patient #
@Rad_Nation It avoids disjointed discussions, decisions by committee, and is much more convenient for patients as it reduces multiple hospital visits. Having already met her RadOnc additional EBRT is not a surprise #radonc #jc https://t.co/WvCo6ZpKws https
@Rad_Nation The other important outcomes were invasive local recurrence-free survival, mastectomy-free survival, distant disease-free survival, overall survival, breast cancer mortality, and non-breast cancer mortality. #radonc #jc https://t.co/WvCo6ZpKws
@Rad_Nation Analysis of conventional longer term outcomes in breast cancer trials needs to include deaths as events for two reasons. Firstly, deaths are one of the most important clinical outcomes. #radonc #jc https://t.co/WvCo6ZpKws
RT @jsvaidya: @Rad_Nation @ElenaSperk The amount of follow up data in TARGIT-A is amongst the highest in trials of different methods of giv…
@Rad_Nation @ElenaSperk The amount of follow up data in TARGIT-A is amongst the highest in trials of different methods of giving PBI for invasive breast cancer #radonc #jc https://t.co/WvCo6ZpKws https://t.co/Rqtv3SCS5X
@Rad_Nation @ElenaSperk The KM figures show the long-term chances of women living without local recurrence, or without needing a mastectomy (to have local recurrence / mastectomy one needs to be alive) #radonc #jc https://t.co/WvCo6ZpKws https://t.co/fiDt
@Rad_Nation @ElenaSperk Protocol specified a 2.5% non-inferiority margin for 5-year local recurrence rates. The follow up was complete for 5-years and the trial confirmed non-inferiority. #radonc #jc https://t.co/WvCo6ZpKws
@Rad_Nation @ElenaSperk The 2.5% non-inferiority margin in the TARGIT-A trial is a relevant, relatively stringent margin. Patient preference studies in the United States, Australia, and Europe suggest that 2.5% is an acceptable margin. #radonc #jc https://
@Rad_Nation @ElenaSperk The original protocol specified that the difference in LR at 5 years should not be more than 2.5%. In the 2013 analysis, it was made more rigorous - that the upper 90% confidence interval of the difference must not exceed 2.5%. #rad
@Rad_Nation @ElenaSperk Therefore, in the original protocol, non-inferiority was specified as being achieved if the difference in the binomial proportions of local recurrence rate at five years did not cross a stringent margin of 2.5% in absolute terms. #r
@Rad_Nation @ElenaSperk Therefore, whether the difference seen between the two randomised arms is statistically significant is not relevant here. As long as the absolute difference is not clinically significant, the new treatment would be deemed non-inferi
@Rad_Nation @ElenaSperk The non-inferiority statistical test for such a comparison is not meant to check for superiority, but to assess if the difference is within an acceptable margin and the experimental treatment is not meaningfully worse than the contr
@Rad_Nation @ElenaSperk Non-inferiority trials in cancer are performed to test new treatments that have obvious non-oncological advantages, such as better access, convenience, or quality of life for the patient, or reduced costs for the healthcare system.
RT @jsvaidya: @Rad_Nation Definite deleterious BRCA mutation was an exclusion criterion. But the majority of breast cancers are sporadic. O…
@SorenBentzen @ElenaSperk @Rad_Nation The experimental treatment was never just TARGIT-IORT. It was TARGIT-IORT with or without EBRT. Therefore 91% of patients received the allocated treatment in the experimental arm - similar to the 92% who received it in
RT @jsvaidya: @Rad_Nation Definite deleterious BRCA mutation was an exclusion criterion. But the majority of breast cancers are sporadic. O…
RT @BreastDocUK: For those wanting a quick intro into today's #radonc #jc topic of IORT in the TARGIT study I recommend the 4min video abst…
RT @BreastDocUK: For those wanting a quick intro into today's #radonc #jc topic of IORT in the TARGIT study I recommend the 4min video abst…
@Rad_Nation We believe patient participation is very important –the trial should be of the patients, by the patients and for the patients. #radonc #jc https://t.co/WvCo6ZpKws
@Rad_Nation Definite deleterious BRCA mutation was an exclusion criterion. But the majority of breast cancers are sporadic. OncotypeDX has not been used to select patients. #radonc #jc https://t.co/WvCo6ZpKws